logo
  

Deutsche Bank, BNP Paribas In Deal For Prime Finance And Electronic Equities

Deutsche Bank AG (DB) announced Monday that it has signed a master transaction agreement with BNP Paribas SA (BNPQY.PK,BNP.L) to provide continuity of service to Deutsche Bank's Global Prime Finance and Electronic Equities clients.

Under the agreement, Deutsche Bank will continue to operate the platform until clients can be migrated to BNP Paribas. The transition for clients will be through the migration of technology and key staff from Deutsche Bank to BNP Paribas. This binding agreement remains subject to regulatory approvals of the relevant authorities.

Bloomberg had reported, citing a people familiar with the matter, that Deutsche Bank was nearing a deal to transfer its prime brokerage business to BNP Paribas.

Frank Kuhnke, Chief Operating Officer, Deutsche Bank, said, "We are pleased to have signed the master transaction agreement with BNP Paribas on schedule. This is an important milestone for our Capital Release Unit and attests to the strength of our client offering and technology in these products. We are already making progress and are on the right track to implement this transaction, thereby providing a clear path for clients and staff."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand. Brooklyn, New York -based Golden Natural Products, Inc. is recalling two dried apricot products as they contain undeclared sulfites, the U.S. Food and Drug Administration said. The recall involves Dried Apricot Subkhon with Bone and Dried Apricot Subkhon Jumbo. Pfizer and Moderna have raised the prices of their respective Covid vaccines for European Union, the Financial Times reported. Pharmaceutical giants renegotiated their covid vaccine supply contract with the EU citing global inflation, supply chain bottleneck and a high demand for the vaccines. A similar price hike is expected in other markets.
Follow RTT